| Name | Title | Contact Details |
|---|---|---|
Benjamin Ehrhart |
Vice President, Assistant General Counsel and Assistant Chief Compliance Officer | Profile |
Ryan Bonistalli |
Compliance Director | Profile |
Stephanie Kim |
Vice President Regulatory Affairs | Profile |
Paul Wickman |
Vice President, Intellectual Property | Profile |
Karah Parschauer |
EVP, General Counsel and Corporate Secretary | Profile |
Diazyme is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility. We provide manufacturing and development support for live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need.
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease. As part of GENFIT’s comprehensive approach to clinical management of NASH patients, the Company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic, or IVD, test to identify patients with NASH who may be appropriate candidates for drug therapy. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 170 employees. GENFIT is a public company listed on the Nasdaq Global Select Market and in compartment B of Euronext’s regulated market in Paris.
Advanced Diagnostic Group is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.